Brief: Anixa Begins FDA-Approved IND Transfer for Phase 2 Breast Cancer Vaccine Trial
04/08/2025 14:15
Aug 4 (Reuters) - Anixa Biosciences Inc ANIX.O: ANIXA BIOSCIENCES ANNOUNCES COMMENCEMENT OF US FDA APPROVED IND TRANSFER TO SUPPORT UPCOMING PHASE 2 BREAST CANCER VACCINE TRIAL Source text: ID:nPn2FKbtja Further company coverage: ANIX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Anixa Biosciences
See all newsBrief: Anixa Biosciences Announces First Case Of Stable Disease For Three Months In Ovarian Cancer Car-T Clinical Trial
US RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
Anixa Biosciences Inc reports results for the quarter ended July 31 - Earnings Summary
Anixa Biosciences Inc expected to post a loss of 9 cents a share - Earnings Preview
Factbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine